Asia-Pacific Opioid Induced Constipation Drug Market Forecast 2017-2025

Publisher Name :
Date: 01-Aug-2017
No. of pages: 54

Key Findings

The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 5.07% during the forecast period of 2017-2025. The market worth is expected to increase from $233 million in 2016 and reach $361.88 million by 2025. The ease in the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market.

Market Insights

The Asian market can be classified on the basis of drug type and prescription type. The drug type is further classified into naloxegol, lubiprostone, and methyl naltrexone bromide and some pipeline drugs such as naldemedine, alvimopan, dolcanatide and elobixibat. The prescription type is classified into generic and branded prescribed drugs and over the counter drugs. A large number of considerations while using opioids is a major challenge currently faced by the market.

Competitive Insights

Some of the major players in the market are

• Daiichi Sankyo Co Ltd

• Pfizer

• Shionogi & Co., Ltd.

• Allergan Plc

• Nektar Therapeutics

• Mundipharma International Limited

• Ono Pharmaceutical Co., Ltd.

• Takeda Pharmaceutical Company Limited

• Cosmo Pharmaceuticals Sa

• Daewoong Pharmaceutical Co

Asia-Pacific Opioid Induced Constipation Drug Market Forecast 2017-2025

Table of Contents

1. Research Scope
1.1. Study Goals
1.2. Scope of the Market Study
1.3. Who Will Find This Report Useful?
1.4. Study and Forecasting Years
2. Research Methodology
2.1. Sources of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. . Top Down Approach
2.3. Bottom Up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
4. Market Overview
4.1. Market Definition
4.2. Key Market Insights
4.3. Attractive Investment Scenario
4.4. Positioning of Key Cic Drugs Manufacturers In the Market
4.5. Market Drivers
4.5.1. Rising Use of Opioid
4.5.2. Increasing Geriatric Population
4.5.3. Easy Availability of Improved and Effective Oic Drugs
4.6. Restraints
4.6.1. Research On Pain and Next Generation Analgesics
4.6.2. Side Effects of Oic Drugs
4.6.3. Unawareness and Ignorance Among Patients
4.7. Opportunity
4.7.1. Rising Demand For Oic Drugs From Apac Market
4.7.2. Increasing Use of Opioids
4.8. Challenges
4.8.1. Large Number of Considerations While Using Opioids
5. Asia Pacific Oic Drug Market By Drug Type 2017-2025 ($ Million)
5.1. Overview
5.1.1. Methyl Naltrexone Bromide
5.1.2. Lubiprostone
5.1.3. Naloxegol
5.2. Pipeline Drug Analysis: Phase 3: Naldemedine (Year of Launch To 2022 $ Million)
5.3. Pipeline Drug Analysis: Phase 2: Alvimopan, Dolcanatide (Qualitative Information)
5.4. Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch To 2022 $ Million)
6. Asia Pacific Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
6.1. Prescribed Drugs
6.1.1. Branded
6.1.2. Generic
6.2. Over the Counter Drugs
7. Key Analytics
7.1. Porters Five Force Model
7.1.1. Intensity of Competitive Rivalryompetition Among The
7.1.2. Bargaining Power of Suppliers
7.1.3. Bargaining Power of Buyers
7.1.4. Threat of Substitute Products
7.1.5. Threat of New Entrants
7.2. Vendor Landscape
7.3. Opportunity Matrix
8. Asia Pacific Oic Drugs Market By Countries 2017-2025 ($ Million)
8.1. China
8.2. Japan
8.3. Rest of Asia Pacific
9. Company Profile
9.1. Ironwood Pharmaceuticals Inc
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Strategic Moves
9.1.4. Scot Analysis
9.2. Daiichi Sankyo Co Ltd
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Strategic Moves
9.2.4. Scot Analysis
9.3. Pfizer
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Strategic Moves
9.3.4. Scot Analysis
9.4. Progenics Pharmaceuticals Inc
9.4.1. Overview
9.4.2. Strategic Moves
9.4.3. Scot Analysis
9.5. Shionogi & Co., Ltd.
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Strategic Moves
9.5.4. Scot Analysis
9.6. Allergan Plc
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Strategic Moves
9.6.4. Scot Analysis
9.7. Nektar Therapeutics
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Strategic Moves
9.7.4. Scot Analysis
9.8. Purdue Pharma L.P.
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Strategic Moves
9.8.4. Scot Analysis
9.9. S.L.A. Pharma Ag
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.10. Mundipharma International Limited
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Strategic Moves
9.10.4. Scot Analysis
9.11. Ono Pharmaceutical Co., Ltd.
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Strategic Moves
9.11.4. Scot Analysis
9.12. Takeda Pharmaceutical Company Limited
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Strategic Moves
9.12.4. Scot Analysis
9.13. Theravance Biopharma Inc
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Strategic Moves
9.13.4. Scot Analysis
9.14. Valeant Pharmaceuticals International
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Strategic Moves
9.14.4. Scot Analysis
9.15. Cosmo Pharmaceuticals Sa
9.15.1. Overview
9.15.2. Product Portfolio
9.15.3. Strategic Moves
9.15.4. Scot Analysis
9.16. Daewoong Pharmaceutical Co., Ltd.
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Strategic Moves
9.16.4. Scot Analysis
9.17. C.B. Fleet Company, Inc.
9.17.1. Overview
9.17.2. Product Portfolio
9.17.3. Strategic Moves
9.17.4. Scot Analysis

List of Tables

Table 1 Asia Pacific Oic Drug Market By Countries 2017-2025 ($ Million)
Table 2 Pharmacological Approaches To Treat Opioid Induced Constipation
Table 3 Laxatives Used For Opioid Induced Constipation
Table 4 Side Effects of Using Laxatives
Table 5 Patients Unfit For Intake of Opioids
Table 6 Asia Pacific Oic Drug Market By Drug Type, 2017-2025 ($ Million)
Table 7 Product Profile (Methyl Naltrexone Bromide)
Table 8 Product Profile (Lubiprostone)
Table 9 Product Profile (Naloxegol)
Table 10 Pipeline Product Profile (Naldemedine)
Table 11 Pipeline Product Profile (Alvimopan, Dolcanatide)
Table 12 Pipeline Product Profile (Elobixibat)
Table 13 Asia Pacific Oic Drug Market By Prescription Type 2017-2025 ($ Million)
Table 14 Product Profile (Lubiprostone)
Table 15 Asia Pacific Prescribed Oic Drugs Market 2017-2025($ Million)
Table 16 Product Profile (Methyl Naltrexone Bromide)
Table 17 Product Profile (Metamucil)
Table 18 Product Profile (Bisacodyl)
Table 19 Asia Pacific Oic Drug Market By Countries 2017-2025 ($ Million)

List of Figures

Figure 1 Asia Pacific Oic Drugs Market 2017-2025 ($ Million)
Figure 2 Asia Pacific Oic Drug Market By Drug Type 2016 and 2025 (%)
Figure 3 Asia Pacific Oic Drug Market By Prescription Type 2016 (%)
Figure 4 Increasing Number of Opioid Prescription ($ Million)
Figure 5 Reasons For the Growth of Opioid Market.
Figure 6 Common Side Effects of Movantik
Figure 7 Major Usage of Opioids
Figure 8 Considerations Taken While the Opioid Usage
Figure 9 Asia Pacific Methyl Naltrexone Bromide Oic Drug Market 2017-2025 ($ Million)
Figure 10 Asia Pacific Lubiprostone Oic Drug Market 2017-2025 ($Million)
Figure 11 Asia Pacific Naloxegol Oic Drug Market 2017-2025 ($ Million)
Figure 12 Asia Pacific Prescribed Oic Drug Market 2017-2025 ($ Million)
Figure 13 Asia Pacific Prescribed Branded Oic Drug Market 2017-2025 ($ Million)
Figure 14 Asia Pacific Prescribed Generic Oic Drug Market 2017-2025 ($ Million)
Figure 15 Asia Pacific Over the Counter Oic Drug Market 2017-2025 ($ Million)
Figure 16 Asia Pacific Oic Drug Market 2017-2025 ($ Million)
Figure 17 China Oic Drug Market 2017-2025 ($ Million)
Figure 18 Pharmaceuticals Market Sales Across the Globe (%)
Figure 19 Japan Oic Drug Market 2017-2025 ($ Million)
Figure 20 Rest of Apac Oic Drug Market 2017-2025 ($ Million)
  • Global Diarrhea Drug Market Professional Survey Report 2017
    Published: 14-Sep-2017        Price: US 3500 Onwards        Pages: 106
    This report studies Diarrhea Drug in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - HPGC - Simcere - Hailisheng - Sichuan Weiao - Shanxi Kangxin......
  • Celiac Disease - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 83
    Celiac Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Ris......
  • Global Irritable Bowel Syndrome Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Irritable Bowel Syndrome Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report pro......
  • Global Esophageal Reflux Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Esophageal Reflux Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides u......
  • Global Peptic Ulcer Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Peptic Ulcer Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides unders......
  • Global Ulcerative Colitis Partnering 2010-2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides ......
  • North America Gastrointestinal Drug Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 01-Sep-2017        Price: US 4480 Onwards        Pages: 121
    Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. Scope of the Report: This report focuses on the Gastrointestinal Drug in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufactu......
  • Global Inflammatory Bowel Disease Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Inflammatory Bowel Disease Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report p......
  • Global Gastrointestinal Symptoms Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Gastrointestinal Symptoms Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report pr......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs